MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · IEX Real-Time Price · USD
0.717
-0.013 (-1.71%)
At close: May 13, 2024, 3:59 PM
0.733
+0.016 (2.16%)
After-hours: May 13, 2024, 7:56 PM EDT
MIRA Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
10.60M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMIRA News
- 5 weeks ago - Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission - PRNewsWire
- 7 weeks ago - MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor - PRNewsWire
- 3 months ago - MIRA Pharmaceuticals Provides Corporate Update - PRNewsWire
- 5 months ago - MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations - PRNewsWire
- 5 months ago - MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% - PRNewsWire
- 6 months ago - MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time - PRNewsWire
- 6 months ago - MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a - PRNewsWire
- 6 months ago - MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 - PRNewsWire